Loading...
•
Jun 30, 2025
Nuvectis Pharma Q2 2025 Earnings Report
Nuvectis Pharma reported increased operating expenses and a wider net loss in the second quarter of 2025 while strengthening its cash position.
Key Takeaways
For Q2 2025, Nuvectis reported a net loss of $6334000 with diluted EPS of -$0.30. Research and development expenses were $3613000 and general and administrative expenses were $2982000. Cash and cash equivalents increased to $26793000 as of June 30, 2025.
Net loss attributable to common shareholders was $6334000.
Research and development expenses totaled $3613000.
General and administrative expenses were $2982000.
Cash and cash equivalents increased to $26793000 compared to year-end 2024.
Forward Guidance
The company expects its strengthened cash position to fund operations into the second half of 2027 while advancing the NXP900 Phase 1b program.
Positive Outlook
- Phase 1a dose escalation study successfully completed.
- Drug-drug interaction study completed.
- Phase 1b program initiation expected imminently.
- Strengthened cash position following ATM transaction.
- Cash runway expected into 2H 2027.
Challenges Ahead
- Continued operating losses.
- Higher R&D expenses year over year.
- Increased G&A expenses year over year.
- No revenue generation.
- Dependence on future clinical milestones.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...